Amitradicain is meticulously formulated to counteract the perilous cascade effects arising during autonomic dysfunction. Such malfunctions can set off a series of escalating physiological challenges, potentially leading to severe outcomes. By targeting key points within this cascade, Amitradicain seeks to halt the onset and progression of these complications, emphasizing a proactive stance in maintaining autonomic balance.

Amitradicain is not a commercially available medication produced by a pharmaceutical company. It is a composite formula. A specialized and experiemced pharmacist must prepare it following a physician’s order, in accordance with the legal framework of the treatment location. This is not a commercial platform for selling the drug. Its primary aim is to disseminate knowledge about this non-patented composite medication to physicians worldwide.

Amitradicaine has been used but 192 physicians on 682 patients worldwide since 2022 after informed consent and within the scope of the local laws, rules and regulations, safety first. The below stated results could be observed. This list is subject to updates as new data will reach the designer of the formula and his lab.

• Marked sympathicolysis, averaging a 62.9% reduction as per AVCB 2.9 evaluations.
• Equilibration of sympathetic and parasympathetic pathways.
• Decrease in catecholaminergic activity by up to 70%, as indicated by body fluid examinations.
• Up to an 80% decline in significant catecholamine surges.
• Noticeable reduction in blood sugar levels, with diabetes symptoms subsiding by the fourth day.
• Reduction in autonomic dysfunction episodes by up to 55%.
• Blood pressure reduced by 20%.
• Significant anxiolysis, especially targeting anxiety stemming from degenerative changes in the substantia nigra and basal ganglia.

Amitradicain is a synergistic combination of highly potent medications, each with its own potential adverse effects and risks. All contraindications and warnings related to Amitradicain’s individual components are applicable. For those with cardiac issues, especially heart failure or blocks, 24/7 monitoring and access to essential life-saving equipment are vital for the initial 90 days of treatment (or longer). This extends even more to those with other cardiovascular or respiratory conditions. Patients on Amitradicain should avoid operating vehicles. Please refer to the interaction guidelines for each ingredient in this formulation. Further warnings and our disclaimer should be read carefully by your physician.

In a specialized network practice dedicated to patients with severe rare diseases, Dr. Ali Asgari, a rather young physician and pharmacologist, was approached by a team facing a perplexing case. The patient was diagnosed with a rare disease marked by intense hypersympathicotonia as well as autonomic dysfunction. Traditional avenues had been exhausted without significant progress.

Recognizing the gravity of the situation, Dr. Asgari embarked on an exhaustive research endeavor. He revisited his old university scripts and textbooks, meticulously analyzing studies and case reports that might offer a hint of a solution. Night after night, he immersed himself in literature, connecting dots from various sources and drawing on his deep knowledge of pharmacology.

It was during one of these intensive study sessions that he recalled a lecture from his academic days. His professor had discussed the potential of synergetic composite medications, emphasizing the benefits that could be harnessed when certain drugs were combined. Inspired by this recollection, Dr. Asgari began formulating a unique composite medication tailored to the patient’s specific needs.

The result was a compound that showed promising effects, offering a new therapeutic avenue for the challenging case at hand. Dr. Asgari’s dedication and rigorous research approach were instrumental in this breakthrough, demonstrating the profound impact of continuous learning and innovation in the medical field.

The result was a compound that showed promising effects, offering a new therapeutic avenue for the challenging case at hand. Recognizing the potential benefits for a wider patient demographic, Dr. Asgari, in a spirit of altruism and dedication to the medical community, decided not to patent the formula. Instead, he openly shared Amitradicain with other clinics, focusing especially on those dealing with rare or even nameless diseases.

As a consequence, Dr. Asgari and LCG Research began receiving a plethora of feedback from various clinics worldwide. This invaluable bedside data, sourced directly from diverse clinical settings, is continuously and meticulously analyzed, ensuring that Amitradicain evolves in line with the real-world needs of patients and clinicians, further exemplifying the commitment of Dr. Asgari to advancing medical knowledge and patient care.

In the realm of rare diseases, ‘Orphan Drugs’ have been the conventional route. However, they often come with laborious development timelines, high costs, and restrictive patents. Amitradicain offers an alternative: a composite formula that leverages the synergetic potential of existing drugs.

Speed of Development

Developed in just over 14 months with the final formula having been available since Summer 2022, Amitradicain defies the traditional timelines associated with pharmaceutical development. Its fast-track status is due to its composition of already approved, fully licensed and well-studied medications as a formula, not a product.

Freedom in therapeutic choices

Originating from a European ethos that permits physicians to prescribe custom formulas at their own risk, Amitradicain takes full advantage of what the Germans call “Therapiefreiheit.” This permits the immediate use of Amitradicain post-informed consent, democratizing access to effective treatment options across global healthcare systems.

Clinical synergy: More than the sum of its parts

Hundreds of physicians worldwide have reported a notable synergetic effect when administering Amitradicain as a composite, compared to using its individual components separately. This phenomenon has driven the unprecedented speed of its acceptance among clinicians treating patients with a pathologically, out of control hypersympathic tone (a clinical situation that can be life-threatening) for whom other medications have failed.

Legality and Liability

Being a composite of existing medications, Amitradicain comes with no attached patents, allowing any qualified pharmacist to produce it (please study the Warnings & Disclaimer section carefully). While we, LCG Research, provide the formula as a philanthropic gift, all liability resides with the prescribing physician. The brand name Amitradicain is only protected to prevent commercial usurpation or misuse.

A gift to global healthcare

By providing Amitradicain as an open-source formula, LCG Research aims to empower physicians and help patients who have run out of options. We are committed to maintaining the integrity of this groundbreaking composite, thereby offering a fresh, effective, and rapid solution to rare diseases that have been hitherto neglected.

Amitradicin is a formulation that must be adapted to a specific patient by a licensed doctor. It is not an industrially prefabricated medicinal product. If a doctor in the EU prescribes a composite medicinal product prepared in a pharmacy, special regulations apply that differ from those for industrially manufactured medicinal products.

Compounded medicines in pharmacies are typically prepared for a specific patient based on a doctor’s prescription. This means the medicine is not manufactured in advance and stored. This applies to Amitradicain.

The preparation of compounded medicines is subject to national laws and must comply with Good Manufacturing Practices (GMP). The pharmacy is responsible for quality assurance. This applies to Amitradicain.

Unlike industrially produced medicines, compounded medicines do not require formal approval from medicinal authorities. However, the pharmacist must ensure that production meets legal requirements.

The prescribing doctor is responsible for deciding to prescribe a custom compounded medicine. The pharmacist is accountable for its correct preparation and dispensation. This applies to Amitradicain.

The pharmacy must keep accurate records of the production process, ingredients used, and dispensation of the medicine. This applies to Amitradicain.

The pharmacist should inform the patient about the use, dosage, and potential side effects of the compounded medicine. In mane EU states it is allowed to prescribe the ingredient seprately with the patient mixing their composite injection themselves. This applies to Amitradicain.w